Equities Analysts Offer Predictions for MLTX Q1 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Stock analysts at Wedbush issued their Q1 2026 earnings estimates for MoonLake Immunotherapeutics in a research report issued on Monday, September 29th. Wedbush analyst Y. Zhong forecasts that the company will post earnings of ($0.63) per share for the quarter. Wedbush has a “Outperform” rating and a $18.00 price target on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share. Wedbush also issued estimates for MoonLake Immunotherapeutics’ Q3 2026 earnings at ($0.88) EPS, Q4 2026 earnings at ($0.91) EPS, FY2027 earnings at ($3.60) EPS and FY2028 earnings at ($2.57) EPS.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.14). During the same period in the prior year, the business earned ($0.39) earnings per share.

Other research analysts also recently issued reports about the company. Redburn Atlantic raised MoonLake Immunotherapeutics to a “hold” rating in a report on Monday, July 28th. Royal Bank Of Canada reissued a “sector perform” rating and set a $10.00 price target (down from $67.00) on shares of MoonLake Immunotherapeutics in a report on Monday. Needham & Company LLC cut their price objective on shares of MoonLake Immunotherapeutics from $66.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday. HC Wainwright lowered shares of MoonLake Immunotherapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday. Finally, Jefferies Financial Group cut MoonLake Immunotherapeutics from a “buy” rating to a “hold” rating and set a $8.00 target price on the stock. in a research report on Monday. Three research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $37.00.

MoonLake Immunotherapeutics Stock Up 5.7%

Shares of MLTX opened at $7.46 on Thursday. The company has a market capitalization of $479.16 million, a price-to-earnings ratio of -2.68 and a beta of 1.11. MoonLake Immunotherapeutics has a 52 week low of $5.95 and a 52 week high of $62.75. The stock’s 50-day moving average price is $50.88 and its 200-day moving average price is $45.26. The company has a quick ratio of 16.65, a current ratio of 16.65 and a debt-to-equity ratio of 0.21.

Insider Buying and Selling at MoonLake Immunotherapeutics

In related news, major shareholder Bihua Chen sold 6,494,151 shares of the firm’s stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $7.21, for a total value of $46,822,828.71. Following the transaction, the insider directly owned 2,000,000 shares of the company’s stock, valued at approximately $14,420,000. This trade represents a 76.45% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 12.02% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

A number of hedge funds have recently made changes to their positions in the company. Deutsche Bank AG boosted its stake in shares of MoonLake Immunotherapeutics by 59.8% in the fourth quarter. Deutsche Bank AG now owns 903 shares of the company’s stock worth $49,000 after acquiring an additional 338 shares during the last quarter. Elevation Point Wealth Partners LLC purchased a new position in MoonLake Immunotherapeutics in the 2nd quarter valued at $74,000. US Bancorp DE lifted its holdings in MoonLake Immunotherapeutics by 114.4% in the 1st quarter. US Bancorp DE now owns 2,208 shares of the company’s stock valued at $86,000 after purchasing an additional 1,178 shares in the last quarter. Quarry LP acquired a new stake in MoonLake Immunotherapeutics during the 1st quarter worth $94,000. Finally, Advisors Asset Management Inc. grew its holdings in shares of MoonLake Immunotherapeutics by 81.7% during the first quarter. Advisors Asset Management Inc. now owns 4,009 shares of the company’s stock worth $157,000 after buying an additional 1,803 shares in the last quarter. Institutional investors and hedge funds own 93.85% of the company’s stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.